Associate Director Community Outreach- 🫁Thoracic Oncology, University of Miami @SylvesterCancer , 🇵🇷Boricua, Co-founder @KidsHelpingKidsSucceed
Miami, FL
Joined June 2012
- Tweets14.6K
- Following3K
- Followers8.5K
- Likes19.2K
🇧🇷 Obrigada, @IASLC! Excited to travel to São Paulo for #LALCA Nov 12-14 and share perspectives on incorporating ADCs and bispecific antibodies into lung cancer management.
🎙️Scientific Session ES10.03
📅 Nov 13 | 11:45 AM
Looking forward to connecting with colleagues across Latin America! 🇧🇷 #LungCancer
Dr. Estela Rodriguez retweeted
Lung cancer screening can detect cancer before symptoms appear, yet many eligible Americans aren't getting screened.
Following Pope Leo’s lung cancer diagnosis, Sylvester’s Dr. Coral Olazagasti (@COlazagasti) spoke with @PreventionMag about barriers to screening, the importance of early detection and why individual risk factors matter. spr.ly/6013BHXrKD
As a Catholic and thoracic oncologist, I’m delighted by the encouraging news about @Pontifex’s recovery and surgical results ! 🙏 His doctors report no need for additional treatment based on pathology and molecular testing—a wonderful outcome of early stage lung cancer 🫁 and prayers answered.
Equally remarkable: final results in just 8 days after surgery, while many patients wait weeks for molecular testing in the advanced setting. This is a reminder that timely results and biomarker testing matter! 💜
Pope Leo XIV’s doctors have confirmed that the tumor removed on October 13 was a lung adenocarcinoma and that the disease was localized.
Dr. Luigi Carbone and Professor Stefano Margaritora said on Wednesday evening that a subsequent oncological assessment has confirmed that “no further treatment is necessary.”
Dr. Estela Rodriguez retweeted
Check out my latest article: The Other Decoupling
In 2009, “decoupling” meant hoping Asia could grow despite an American downturn. Today, it means deliberately weakening US–China connections.
Returning to Singapore in 2026, I reread a letter I wrote during the financial crisis—and saw what years of investment in healthcare had built.
“The Other Decoupling” reflects on a lesson for families and countries alike: protection against uncertainty has to be built before it is needed.
linkedin.com/pulse/other-dec… via @LinkedIn
I see @dan_morgen @HemOncMiami fellow in this picture. I know Dr Edith Mitchell @eaonc would have loved to meet him and all these talented trainees- her legacy of creating opportunity and supporting a diverse physician scientist workforce lives on! #Representationmatters
Congratulations to the Fall 2026 Edith Peterson Mitchell, MD Health Equity Travel Scholars: Kamryn Clay, @belladreyfuss25, Dr. Ekpenyong, Dr. Gabra, Alaina Hawkins, @xlabissieremd, @dan_morgen, @PhyuNaing4, @OgaKingsley, & Kennedy Stacy #CancerResearch #ClinicalTrials #eaonc
Dr. Estela Rodriguez retweeted
🫁🧬 Sincere thanks to @eaonc for inviting me back as a former Edith Peterson Mitchell Award recipient to share our ongoing research at @SylvesterCancer.
My talk focused on two important aspects of lung cancer research:
🌍 Understanding the evolving epidemiology and global burden of lung cancer risk factors.
🧬 Exploring how genomic alterations and the tumor immune landscape differ across age groups.
Grateful for the opportunity to share our work and connect with fellow investigators! @GlopesMd @Latinamd @dan_morgen @HemOncMiami @DesaiP_Oncdoc @BenBleibergMD
Dr. Estela Rodriguez retweeted
How do you balance toxicity risks with the potential for improved outcomes?
Watch as experts @Latinamd, Matthew Gumbleton, MD, PhD, of @huntsmancancer, and Siddhartha Devarakonda, MD, of @ProvSwedish, discuss the conversations they have with patients when weighing treatment-related adverse effects against survival benefits in EGFR-mutated NSCLC.
Watch now: hubs.li/Q04z20T40
#NSCLC #LungCancer #Oncology
Dr. Estela Rodriguez retweeted
We reported a 42.9% five-year relative survival rate for malignant brain and nervous system cancers, compared with 32.9% nationally, for cases diagnosed from 2016–2022. The figures are not risk-adjusted.
Learn how Sylvester’s Brain Tumor Institute is advancing personalized care: spr.ly/6012BHnANK
Dr. Estela Rodriguez retweeted
As @RajaFlores points out, oncology has a language problem, including how to define "early stage". cancerletter.com/perspective…
For patients & families "early stage" sounds reassuring:
✅ Caught early
✅ Treated
✅ Cured
But in #lungcancer, even stages I and II have a significant risk of recurrence. I know firsthand how devastating it is to be diagnosed with Stage Ia, believe I'm cured, experience recurrence, and learn I have advanced-stage disease.
Of course staging matters. But stage is not a prognosis, and patients aren't statistics. For patients and families, the real question is, "What does that stage mean for me, my family, my life?"
Because understanding your stage is not the same as understanding your cancer.
#LCSM #WordsMatter #staging @TheCancerLetter @DrewMoghanaki
Dr. Estela Rodriguez retweeted
Getting ready for @myesmo #ESMO26?
Here are the top ten #LCSM presentations by @oncoalert
@SclcSMASHERS @FDA @LUNGevity @lungoncdoc @StephenVLiu @HHorinouchi @g_mountzios @sands_jacob @LauraAlderMD @oncodaily @OncoAlert @Latinamd @LuisPaz_Ares @RManochakian @LuisRaezMD @triparnasen @LaurenByersMD @LungCancerEu @alissajcooper @BZhangMD @NaglaAKarimMD @Annechiangmd @IASLC @NCCN @ASCO #ESMO26 @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @colazagasti @openmedicineHQ @myesmo @openmedkate @openmedben @chadinabhan @YoungLungCancer @OncodailyLung @ClinicalLung #LCSM @LungPolicy @dan_morgxen
🚨 #ESMO26 Lung Cancer: Top Ten by @OncoAlert 🫁
The abstracts our faculty picked as must-know from Madrid 👇
1️⃣ DeLLphi-305 (LBA3): tarlatamab + durvalumab, 1L maintenance in ES-SCLC
2️⃣ Krascendo 1 (LBA5): divarasib vs sotorasib/adagrasib in KRAS G12C NSCLC
3️⃣ SAFFRON (LBA6): osimertinib + savolitinib in EGFRm MET+ NSCLC post-osimertinib
4️⃣ OptiTROP-Lung04 (LBA67): final OS, sac-TMT vs chemo after EGFR-TKI
5️⃣ OptiTROP-Lung06 (LBA66): sac-TMT + pembro, 1L PD-L1-negative non-squamous NSCLC
6️⃣ PERSEE (2614O): pembro ± chemo, 1L PD-L1 ≥50%
7️⃣ SANOVO (LBA69): savolitinib + osimertinib, 1L EGFRm MET-overexpressed NSCLC
8️⃣ IFCT-2103 DIAL (2618RO): continue pembro vs observation at 6 months
9️⃣ PANKU-Lung01 (LBA71): iza-bren after third-generation EGFR TKI
🔟 SARON (2613O): consolidation radiotherapy in oligometastatic NSCLC
#lcsm #OncoAlert #MedTwitter
Pinging our OncoAlert Lung Cancer Faculty
@christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD
@peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @LeciaSequist @bensolomon1 @VanitaNoronha +@alexdrilon @JordiRemon @caliraf @JulienMazieres @TerriConneran
5️⃣ days to go for @flasco_voiceofoncology Women’s Cancer Care Conference -
a full day of panels dedicated to women’s health across the cancer continuum from diagnosis to survivorship
📆Saturday, October 24, 2026, 8:20 am to 4PM
📍Hotel Colonnade Coral Gables
📖 5.5 CME
FREE for @FLASCO_ORG members
@sylvestercancer
Register at flasco.org/events/cos-flasco…
👏👏Great to see two former members of the @SylvesterCancer Thoracic Working Group listed as presenters at the Fall @eaonc Young Investigator Symposium- @FahminB_MDPhD now @DukeCancer and @Jani_Chinmay now faculty @SylvesterCancer #proudmentor
Meet the 2026 ECOG-ACRIN Young Investigator Symposium presenters, who will share innovative #CancerResearch tomorrow in Philadelphia: bit.ly/YIS26
@JithmaA @FahminB_MDPhD @FedGhali @Jani_Chinmay @CathyHandy @ShachiMittal2 @fangdisun @VarshaS53228024 & Allison Matous
👇 Submit your comments for @ASCO Guidelines for Mgmt of irAEs by November 2: bit.ly/4i6DUck
Our draft guideline recommendations for “Management of Immune-Related Adverse Events- Gastrointestinal and Endocrine Toxicities” are now open for public comment.
Submit your comments to us by November 2: bit.ly/4i6DUck
Dr. Estela Rodriguez retweeted
One of my most anticipated #ESMO26 presentations:
Krascendo 1 (LBA5) — phase III divarasib vs sotorasib/adagrasib in previously treated KRAS G12C+ NSCLC.
Roche reports positive PFS and interim OS results.
But the effect sizes and full safety data are still pending.
Dr. Estela Rodriguez retweeted
Strong institutions. Shared purpose. Lasting progress. Our members are changing the future of cancer control!
As @UICC approaches its General Assembly tomorrow, I reflect with gratitude on the privilege of serving on its Board and chairing the ATOM Coalition.
Our experiences expanding access to cancer medicines, advancing cancer policy through IASLC, and working with partners across countries have reinforced three lessons:
Evidence must inform policy.
Policy must translate into delivery.
Lasting progress depends on people and institutions.
None of this work happens alone. Credit belongs to UICC’s members, staff, patient advocates, clinicians, policymakers, and partners worldwide.
I am honored to be a candidate for President-elect and grateful for the conversations, ideas, and encouragement shared throughout this process.
The true measure of leadership is what we enable others to achieve.
Whatever tomorrow brings, our shared mission continues.
#UICC #CancerControl #GlobalOncology
@SclcSMASHERS @FDA @LUNGevity @lungoncdoc @StephenVLiu @HHorinouchi @g_mountzios @sands_jacob @LauraAlderMD @oncodaily @OncoAlert @Latinamd @LuisPaz_Ares @RManochakian @LuisRaezMD @triparnasen @LaurenByersMD @LungCancerEu @alissajcooper @BZhangMD @NaglaAKarimMD @Annechiangmd @IASLC @NCCN @ASCO #WCLC26 @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @colazagasti @openmedicineHQ @myesmo @openmedkate @openmedben @chadinabhan @YoungLungCancer @OncodailyLung @ClinicalLung #LCSM @LungPolicy @dan_morgxen
Dr. Estela Rodriguez retweeted
Inspiring closing plenary from neoadjuvant star #TinaCascone @MDAndersonNews, key innovations:
- new preclinical models for neoadj ICI
- novel trial designs such as NEOCOAST2 as a translational platform
- clinical insights: eg nodal flare, microbiome
@IrishLungCancer #LCSM
